We are pleased to announce that Jennifer Che, Managing Director of Eagle IP, will be traveling to London from May 2 to May 6, 2026  in conjunction with the International Trademark Association (INTA) 2026 Annual Meeting..

If you or your team will be attending INTA2026 or will be in London during the first week of May, Jennifer would welcome the opportunity to meet for a coffee or a scheduled briefing. Please contact us to coordinate a time during the conference week.

Our Past Events

Pauli Wong, joined HKSTP Global Connect Market Discovery: Your Cross-Border Playbook as a panel speaker

4 November 2026

Jennifer Che and Pauli Wong Co-Teach Advanced Patent Skills Seminar at HKU-TEC

15 October 2026

Pauli Wong gave a talk at Hong Kong Life Sciences Society (HKLSS)

10 October 2026

BioHK2026 | Biotech IP in practice

16 September 2026

Jennifer Che Once Again Named to the IAM Strategy 300

21 August 2026

Yolanda Wang attended the 1st China Pharmaceutical Innovation Conference

22 July 2026

Recommended Insights

Breaking News: China passes Fourth Amendment to the Chinese Patent Law

19 October 2020
After 12 years, the Fourth Amendment to the Chinese Patent Law has passed and will be in effect on 1 Jun 2021. After years of multiple draft amendments that moved in various directions, we FINALLY have some clarity on what patent protection is going to look like in China in the coming future. Many of […]
Read more >

What Microsoft’s Recent Patent Invalidation Case in China Teaches Us About User Interface Patents

29 January 2026
Each year the CNIPA publishes its Top Ten Patent Re-examination and Invalidation Cases for the previous year. These cases are meant to be guiding cases, showcasing exemplary real-world decisions that clarify certain aspects of the law. Today we’ll be sharing about one of the Top 10 Invalidation Cases in 2024 involving Microsoft (China) Co., Ltd. […]
Read more >

Breaking News: Newest Draft Amendment to the Chinese Patent Law Available for Public Comment

10 July 2020
Finally, after more than a year since the last draft amendment came out in 2019, a new draft has been submitted to the National People’s Congress Standing Committee for deliberation on June 28, 2020. The newest version is now published for public comments until August 16, 2020. As a whole, these proposed changes address a […]
Read more >

A Stratification Too Far? How the CNIPA Draws the Line on Patient Subgroups in a Recent Precision Medicine Invalidation Case

27 February 2026
Precision medicine is rapidly transforming the global healthcare landscape, providing more effective therapies and better patient outcomes through targeted solutions. As therapeutics move away from the traditional “one-size-fits-all” model, unique challenges are presented in the patent examination process. The 2024 Top 10 Patent Re-examination and Invalidation case highlighted below provides further insight into how the […]
Read more >
Top crossarrow-right